



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 590 747 A2**

EUROPEAN PATENT APPLICATION

Application number: 93250268.5

Date of filing: 29.09.93

Int. Cl.5: C12N 15/54, C12N 9/10,
C12N 15/12, C07K 13/00,
C12N 15/86, C12N 15/64,
C12N 5/10

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

Priority: 01.10.92 US 955041

Date of publication of application:
06.04.94 Bulletin 94/14

Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

Applicant: LA JOLLA CANCER RESEARCH
FOUNDATION
10901 North Torrey Pines Road
La Jolla, CA 92037(US)

Inventor: Fukuda, Minoru
2818 Passy Avenue
San Diego, California 92122(US)
Inventor: Blerhulzen, Marti F. A.
Schiedamseweg 225
NL-3119 JB Schiedam(US)

Representative: UEXKÜLL & STOLBERG
Patentanwälte
Beselerstrasse 4
D-22607 Hamburg (DE)


A novel-beta1- 6 N-acetylglucosaminyltransferase, its acceptor molecule, leukosialin, and a method for cloning proteins having enzymatic activity.

The present invention provides a novel $\beta 1 \rightarrow 6$ N-acetylglucosaminyltransferase, which forms core 2 oligosaccharide structures in O-glycans, and a novel acceptor molecule, leukosialin, CD43, for core 2 $\beta 1 \rightarrow 6$ N-acetylglucosaminyltransferase activity. The amino acid sequences and nucleic acid sequences encoding these molecules, as well as active fragments thereof, also are disclosed. A method for isolating nucleic acid sequences encoding proteins having enzymatic activity is disclosed, using CHO cells that support replication of plasmid vectors having a polyoma virus origin of replication. A method to obtain a suitable cell line that expresses an acceptor molecule also is disclosed.

EP 0 590 747 A2

EP 0 590 747 A2

FIG. 1



EP 0 590 747 A2

This work was supported by grants CA33000 and CA33895 awarded by the National Cancer Institute. The United States Government has certain rights in this invention.

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

This invention relates generally to the fields of biochemistry and molecular biology and more specifically to a novel human enzyme, UDP-GlcNAc:Gal β 1 \rightarrow 3GalNAc (GlcNAc to GalNAc) β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase (core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase; C2GnT), and to a novel acceptor molecule, leukosialin, CD43, for core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase action. The invention additionally relates to DNA sequences encoding core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase and leukosialin, to vectors containing a C2GnT DNA sequence or a leukosialin DNA sequence, to recombinant host cells transformed with such vectors and to a method of transient expression cloning in CHO cells for identifying and isolating DNA sequences encoding specific proteins, using CHO cells expressing a suitable acceptor molecule.

BACKGROUND INFORMATION

Most *O*-glycosidic oligosaccharides in mammalian glycoproteins are linked via *N*-acetylgalactosamine to the hydroxyl groups of serine or threonine. These *O*-glycans can be classified into 4 different groups depending on the nature of the core portion of the oligosaccharides (see Fig. 1). Although less well studied than *N*-glycans, *O*-glycans likely have important biological functions. Indeed, the presence of *O*-linked oligosaccharides with the core 2 branch, Gal β 1 \rightarrow 3(GlcNAc β 1 \rightarrow 6)GalNAc, has been demonstrated in many biological processes.

Piller et al., *J. Biol. Chem.* 263:15148-15150 (1988) reported that human T-cell activation is associated with the conversion of core 1-based tetrasaccharides to core 2-based hexasaccharides on leukosialin, a major sialoglycoprotein present on human T lymphocytes (see also Fig. 1). A similar increase in hexasaccharides was observed in peripheral blood lymphocytes of patients suffering from T-cell leukemias (Saitoh et al., *Blood* 77:1491-1499 (1991)), myelogenous leukemias (Brockhausen et al., *Cancer Res.* 51:1257-1263 (1991)) and immunodeficiency due to AIDS and the Wiskott-Aldrich syndrome (Piller et al., *J. Exp. Med.* 173:1501-1510 (1991)). In these patients' lymphocytes, changes in the amount of hexasaccharides were caused by increased activity of either UDP-GlcNAc:Gal β 1 \rightarrow 3GalNAc (GlcNAc to GalNAc) 6- β -D-*N*-acetylglucosaminyltransferase (EC2.4.1.102) or core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase (Williams et al., *J. Biol. Chem.* 255:11253-11261 (1980)). Increased activity of core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase also was observed in metastatic murine tumor cell lines as compared to their parental, non-metastatic counterparts (Yousefi et al., *J. Biol. Chem.* 266:1772-1782 (1991)).

Increased complexity of the attached oligosaccharides increases the molecular weight of the glycoprotein. For example, leukosialin containing hexasaccharides has a molecular weight of ~135kDa, whereas leukosialin containing tetrasaccharides has a molecular weight of ~105kDa (Carlsson et al., *J. Biol. Chem.* 261:12779-12786 and 12787-12795 (1986)).

Fox et al., *J. Immunol.* 131:762-767 (1983) raised a monoclonal antibody, T305, against human T-lymphocytic leukemia cells. Sportsman et al., *J. Immunol.* 135:158-164 (1985) reported T305 binding was abolished by neuraminidase treatment, suggesting T305 binds to hexasaccharides. T305 specifically reacts with the high molecular weight form of leukosialin (Saitoh et al., *supra*, (1991)).

Previous studies indicated poly-*N*-acetylglucosamine repeats extend almost exclusively from the branch formed by the core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase (Fukuda et al., *J. Biol. Chem.* 261:12796-12806 (1986)). Consistent with these results, Yousefi et al., *supra*, (1991) demonstrated that the core 2 enzyme in metastatic tumor cells regulates the level of poly-*N*-acetylglucosamine synthesis in *O*-linked oligosaccharides.

Poly-*N*-acetylglucosamines are subject to a variety of modifications, including the formation of the sialyl Le^x, NeuNAc α 2 \rightarrow 3Gal β 1 \rightarrow 4(Fuc α 1 \rightarrow 3)GlcNAc-, or the sialyl Le^a, NeuNAc α 2 \rightarrow 3Gal β 1 \rightarrow 3(Fuc α 1 \rightarrow 4)GlcNAc-, determinants (Fukuda, *Biochim. Biophys. Acta* 780:119-150 (1985)). Such modifications are significant because these determinants, which are present on neutrophils and monocytes, serve as ligands for E- and P-selectin present on endothelial cells and platelets, respectively (see, for example, Larsen et al., *Cell* 63:467-474 (1990)).

In addition, tumor cells often express a significant amount of sialyl Le^x and/or sialyl Le^a on their cell surfaces. The interaction between E-selectin or P-selectin and these cell surface carbohydrates may play a

EP 0 590 747 A2

role in tumor cell adhesion to endothelium during the metastatic process (Walz et al., *supra*, (1990)). Kojima et al., *Biochem. Biophys. Res. Commun.* 182:1288-1295 (1992) reported that selectin-dependent tumor cell adhesion to endothelial cells was abolished by blocking O-glycan synthesis. Complex sulfated O-glycans also may serve as ligands for the lymphocyte homing receptor, L-selectin (Imai et al., *J. Cell Biol.* 113:1213-1221 (1991)).

These reported observations establish core 2 β 1 \rightarrow 6 N-acetylglucosaminyltransferase as a critical enzyme in O-glycan biosynthesis. The availability of core 2 β 1 \rightarrow 6 N-acetylglucosaminyltransferase will allow the *in vivo* and *in vitro* production of specific glycoproteins having core 2 oligosaccharides and subsequent study of these variant O-glycans on cell-cell interactions. For example, core 2 β 1 \rightarrow 6 N-acetylglucosaminyltransferase is a useful marker for transformed or cancerous cells. An understanding of the role of core 2 β 1 \rightarrow 6 N-acetylglucosaminyltransferase in transformed and cancerous cells may elucidate a mechanism for the aberrant cell-cell interactions observed in these cells. In order to understand the control of expression of these oligosaccharides and their function, isolation of a cDNA clone for core 2 β 1 \rightarrow 6 N-acetylglucosaminyltransferase is a prerequisite. However, the DNA sequence encoding core 2 β 1 \rightarrow 6 N-acetylglucosaminyltransferase has not yet been reported.

Thus, a need exists for identifying the core 2 β 1 \rightarrow 6 N-acetylglucosaminyltransferase and the DNA sequences encoding this enzyme. The present invention satisfies this need and provides related advantages as well.

20 SUMMARY OF THE INVENTION

The present invention generally relates to a novel purified human β 1 \rightarrow 6 N-acetylglucosaminyltransferase. A cDNA sequence encoding a 428 amino acid protein having β 1 \rightarrow 6 N-acetylglucosaminyltransferase activity also is provided. The purified human β 1 \rightarrow 6 N-acetylglucosaminyltransferase, or an active fragment thereof, catalyzes the formation of critical branches in O-glycans.

The invention further relates to a novel purified acceptor molecule, leukosialin, CD43, for core 2 β 1 \rightarrow 6 N-acetylglucosaminyltransferase activity. The leukosialin cDNA encodes a novel variant leukosialin, which is created by alternative splicing of the genomic leukosialin DNA sequence.

Isolated nucleic acids encoding either core 2 β 1 \rightarrow 6 N-acetylglucosaminyltransferase or leukosialin are disclosed, as are vectors containing the nucleic acids and recombinant host cells transformed with such vectors. The invention further provides methods of detecting such nucleic acids by contacting a sample with a nucleic acid probe having a nucleotide sequence capable of hybridizing with the isolated nucleic acids of the present invention. The core 2 β 1 \rightarrow 6 N-acetylglucosaminyltransferase and leukosialin amino acid and nucleic acid sequences disclosed herein can be purified from human cells or produced using well known methods of recombinant DNA technology.

The invention also discloses a method of isolating nucleic acid sequences encoding proteins that have an enzymatic activity. Such a nucleic acid sequence is obtained by transfecting the nucleic acid, which is contained within a vector having a polyoma virus replication origin, into a Chinese hamster ovary (CHO) cell line simultaneously expressing polyoma virus large T antigen and the acceptor molecule for the protein having an enzymatic activity.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the structures and biosynthesis of O-glycans. Structures of O-glycan cores can be classified into 4 groups (core 1 to core 4), each of which is synthesized starting with GalNAc α 1 \rightarrow Ser/Thr. The core 1 structure is synthesized by the addition of a β 1 \rightarrow 3 Gal residue to the GalNAc residue. The core 1 structure can be converted to core 2 by the addition of a β 1 \rightarrow 6 N-acetylglucosaminyl residue. This intermediate is usually converted to the hexasaccharide by sequential addition of galactose and sialic acid residues (bottom right). The core 2 β 1 \rightarrow 6 N-acetylglucosaminyltransferase and the linkage formed by the enzyme are indicated by a box. In certain cell types, the core 2 structure can be extended by the addition of N-acetylglucosamine (Gal β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3) repeats to form poly-N-acetylglucosamine. In the absence of core 2 β 1 \rightarrow 6 N-acetylglucosaminyltransferase, core 1 is converted to the monosialoform, then to the disialoform by sequential addition of α 2 \rightarrow 3- and α 2 \rightarrow 6-linked sialic acid residues (bottom left). Alternatively, core 3 can be synthesized by the addition of a β 1 \rightarrow 3 N-acetylglucosaminyl residue to the GalNAc residue. Core 3 can be converted to core 4 by another β 1 \rightarrow 6 N-acetylglucosaminyltransferase (top of figure).

Figure 2 depicts genomic DNA sequence (SEQ. ID. NO. 1) and cDNA sequence (SEQ. ID. NO. 1) of leukosialin. The genomic sequence is numbered relative to the transcriptional start site. Exon 1 and exon 2 have been previously described. Exon 1' is newly identified here. In the isolated cDNA, exon 1' is

EP 0 590 747 A2

immediately followed by the exon 2 sequence. Deduced amino acids (SEQ. ID. NO. 2) are presented under the coding sequence, which begins in exon 2. A portion of the exon 2 sequence is shown.

Figure 3 establishes the ability of pGT/hCG to replicate in CHO cell lines expressing polyoma large T antigen and leukosialin. In panel A, six clonal CHO cell lines were examined for replication of pcDNAI-based pGT/hCG (lanes 1-6). In panel B, replication of cell clone 5 (CHO-Py-leu), was further examined by treatment with increasing concentrations of DpnI and XhoI (lanes 2 and 3). Plasmid DNA isolated from MOP-8 cells was used as a control (lane 1). Plasmid DNA was extracted using the Hirt procedure and samples were digested with XhoI and DpnI. In parallel, pGT/hCG plasmid purified from *E. coli* MC1061/P3 was digested with XhoI and DpnI (lane 7 in panel A and lane 4 in panel B) or XhoI alone (lane 8 in panel A and lane 5 in panel B). The arrow indicates the migration of plasmid DNA resistant to DpnI digestion. The arrowheads indicate plasmid DNA digested by DpnI.

Figure 4 shows the expression of T305 antigen expressed by pcDNAI-C2GnT. Subconfluent CHO-Py-leu cells were transfected with pcDNAI-C2GnT (panels A and B) or mock-transfected with pcDNAI (panels C and D). Sixty four hours after transfection, the cells were fixed, then incubated with mouse T305 monoclonal antibody followed by fluorescein isocyanate-conjugated sheep anti-mouse IgG (panels A, B and C). Two different areas are shown in panels A and B. Panel D shows a phase micrograph of the same field shown in panel C. Bar = 20 μ m.

Figure 5 depicts the cDNA sequence (SEQ. ID. NO. 3) and translated amino acid sequences (SEQ. ID. NO. 4) of core 2 β 1-6 *N*-acetylglucosaminyltransferase. The open reading frame and full-length nucleotide sequence of C2GnT are shown. The signal/membrane-anchoring domain is doubly underlined. The polyadenylation signal is boxed. Potential *N*-glycosylation sites are marked with asterisks. The sequences are numbered relative to the translation start site.

Figure 6 shows the expression of core 2 β 1-6 *N*-acetylglucosaminyltransferase mRNA in various cell types. Poly(A)⁺ RNA (11 μ g) from CHO-Py-leu cells (lane 1), HL-60 promyelocytes (lane 2), K562 erythrocytic cells (lane 3), and SP and L4 colonic carcinoma cells (lanes 4 and 5) was resolved by electrophoresis. RNA was transferred to a nylon membrane and hybridized with a radiolabeled fragment of pPROTA-C2GnT. Migration of RNA size markers is indicated.

Figure 7 illustrates the construction of the vector encoding the protein A-C2GnT fusion protein. The cDNA sequence corresponding to Pro³⁸ to His⁴²⁸ was fused in frame with the IgG binding domain of *S. aureus* protein A (bottom; SEQ. ID. NOS. 7 and 8). The sequence includes the cleavable signal peptide, which allows secretion of the fused protein. The coding sequence is under control of the SV40 promoter. The remainder of the vector sequence shown was derived from rabbit β -globin gene sequences, including an intervening sequence (IVS) and a polyadenylation signal (An).

35 DETAILED DESCRIPTION OF THE INVENTION

The present invention generally relates to a novel human core 2 β 1-6 *N*-acetylglucosaminyltransferase. The invention further relates to a novel method of transient expression cloning in CHO cells that was used to isolate the cDNA sequence encoding human core 2 β 1-6 *N*-acetylglucosaminyltransferase (C2GnT). The invention also relates to a novel human leukosialin, which is an acceptor molecule for core 2 β 1-6 *N*-acetylglucosaminyltransferase activity.

Cells generally contain extremely low amounts of glycosyltransferases. As a result, cDNA cloning based on screening using an antibody or a probe based on the glycosyltransferase amino acid sequence has met with limited success. However, isolation of cDNAs encoding various glycosyltransferases can be achieved by transient expression of cDNA in recipient cells.

Successful application of the transient expression cloning method to isolate a cDNA sequence encoding a glycosyltransferase requires an appropriate recipient cell line. Ideal recipient cells should not express the glycosyltransferase of interest. As a result, the recipient cells would normally lack the oligosaccharide structure formed by such a glycosyltransferase.

Expression of the cloned glycosyltransferase cDNA in the recipient cell line should result in formation of the specific oligosaccharide structure. The resultant oligosaccharide can be identified using a specific antibody or lectin that recognizes the structure. The recipient cell line also must support replication of an appropriate plasmid vector.

COS-1 cells initially appear to satisfy the requirements for using the transient expression method. COS-1 cells express SV40 large T antigen and support the replication of plasmid vectors harboring a SV40 replication origin (Gluzman et al., *Cell* 23:175-182 (1981)). Although COS-1 cells, themselves, express a variety of glycosyltransferases, COS-1 cells have been used to clone cDNA sequences encoding human blood group Lewis α 1-3/4 fucosyltransferase and murine α 1-3 galactosyltransferase (Kukowska-Latallo et

EP 0 590 747 A2

al., *Genes and Devel.* 4:1288-1303 (1990); Larsen et al., *Proc. Natl. Acad. Sci. USA* 86:8227-8231 (1989)). Also, Goelz et al., *Cell* 63:175-182 (1990), utilized an antibody that inhibits E-selectin mediated adhesion to isolate a cDNA sequence encoding $\alpha 1 \rightarrow 3$ fucosyltransferase.

An attempt was made to use COS-1 cells to isolate cDNA clones encoding core 2 $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase. COS-1 cells were transfected using cDNA obtained from activated human T cells, which express the core 2 $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase. Transfected cells suspected of expressing core 2 $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase in the transfected cells were identified by the presence of increased levels of the core 2 oligosaccharide structure formed by core 2 $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase activity. The presence of the core 2 structure was identified using the monoclonal antibody, T305, which identifies a hexasaccharide on leukosialin. A clone expressing high levels of the T305 antigen was isolated and sequenced.

Surprisingly, transfection using COS-1 cells resulted in the isolation of a cDNA clone encoding a novel variant of human leukosialin, which is the acceptor molecule for core 2 $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase activity. Examination of the cDNA sequence of the newly isolated leukosialin revealed the cDNA sequence was formed as a result of alternative splicing of exons in the genomic leukosialin DNA sequence. Specifically, the newly isolated leukosialin is encoded by cDNA sequence containing a previously undescribed non-coding exon at the 5'-terminus (exon 1' in Figure 2; SEQ. ID. NO. 1).

The unexpected result obtained using COS-1 cells led to the development of a new transfection system to isolate a cDNA sequence encoding core 2 $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase. CHO cells, which do not normally express the T305 antigen, were transfected with DNA sequences encoding human leukosialin and the polyoma virus large T antigen. A cell line, designated CHO-Py-leu, which expresses human leukosialin and polyoma virus large T antigen, was isolated.

CHO-Py-leu cells were used for transient expression cloning of a cDNA sequence encoding core 2 $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase. CHO-Py-leu cells were transfected with cDNA obtained from human HL-60 promyelocytes A plasmid, pcDNA1-C2Gnt, which directed expression of the T305 antigen, was isolated and the cDNA insert was sequenced (see Figure 5; SEQ. ID. NO. 3). The 2105 base pair cDNA sequence encodes a putative 428 amino acid protein (SEQ. ID. NO. 4). The genomic DNA sequence encoding can be isolated using methods well known to those skilled in the art, such as nucleic acid hybridization using the core 2 $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase cDNA disclosed herein to screen, for example, a genomic library prepared from HL-60 promyelocytes.

An enzyme similar to the disclosed human core 2 $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase has been purified from bovine tracheal epithelium (Ropp et al., *J. Biol. Chem.* 266:23863-23871 (1991), which is incorporated herein by reference. The apparent molecular weight of the bovine enzyme is ~69kDa. In comparison, the predicted molecular weight of the polypeptide portion of core 2 $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase is ~50kDa. The deduced amino acid sequence of core 2 $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase reveals two to three potential *N*-glycosylation sites, suggesting *N*-glycosylation and *O*-glycosylation, or other post-translational modification, could account for the larger apparent size of the bovine enzyme.

Expression of the cloned C2Gnt sequence, or a fragment thereof, directed formation of the specific *O*-glycan core 2 oligosaccharide structure. Although several cDNA sequences encoding glycosyltransferases have been isolated (Paulson and Colley, *J. Biol. Chem.* 264:17615-17618 (1989); Schachter, *Curr. Opin. Struct. Biol.* 1:755-765 (1991), which are incorporated herein by reference), C2Gnt is the first reported cDNA sequence encoding an enzyme involved exclusively in *O*-glycan synthesis.

In *O*-glycans, $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyl linkages may occur in both core 2, Gal $\beta 1 \rightarrow 3$ (GlcNAc $\beta 1 \rightarrow 6$)-GalNAc, and core 4, GlcNAc $\beta 1 \rightarrow 3$ (GlcNAc $\beta 1 \rightarrow 6$)GalNAc, structures (Brockhausen et al., *Biochemistry* 24:1866-1874 (1985), which is incorporated herein by reference. In addition, $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyl linkages occur in the side chains of poly-*N*-acetylglucosamine, forming the I-structure (Piller et al., *J. Biol. Chem.* 259:13385-13390 (1984), which is incorporated herein by reference), and in the side chain attached to α -mannose of the *N*-glycan core structure, forming a tetraantennary saccharide (Cummings et al., *J. Biol. Chem.* 257:13421-13427 (1982), which is incorporated herein by reference). The enzymes responsible for these linkages all share the unique property that Mn^{2+} is not required for their activity.

Although it was originally suggested that these $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyl linkages were formed by the same enzyme (Piller et al., 1984), the present disclosure clearly demonstrates that the HL-60-derived core 2 $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase is specific for the formation only of *O*-glycan core 2. This result is consistent with a recent report demonstrating that myeloid cell lysates contain the enzymatic activity associated with core 2, but not core 4, formation (Brockhausen et al., *supra*, (1991)).

Analysis of mRNA isolated from colonic cancer cells indicated core 2 $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase is expressed in these cells. Recent studies using affinity absorption suggested at least two different

EP 0 590 747 A2

β 1 \rightarrow 6 *N*-acetylglucosaminyltransferases were present in tracheal epithelium (Ropp et al., *supra*, (1991)). One of these transferases formed core 2, core 4, and I structures. Thus, at least one other β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase present in epithelial cells can form core 2, core 4 and I structures. Similarly, a β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase present in Novikoff hepatoma cells can form both core 2 and I structures (Koenderman et al., *Eur. J. Biochem.* 168:199-208 (1987), which is incorporated herein by reference).

The acceptor molecule specificity of core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase is different from the specificity of the enzymes present in tracheal epithelium and Novikoff hepatoma cells. Thus, a family of β 1 \rightarrow 6 *N*-acetylglucosaminyltransferases can exist, the members of which differ in acceptor specificity but are capable of forming the same linkage. Members of this family are isolated from cells expressing β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase activity, using, for example, nucleic acid hybridization assays and studies of acceptor molecule specificity. Such a family was reported for the α 1 \rightarrow 3 fucosyltransferases (Weston et al., *J. Biol. Chem.* 267:4152-4160 (1992), which is incorporated herein by reference).

The formation of the core 2 structure is critical to cell structure and function. For example, the core 2 structure is essential for elongation of poly-*N*-acetylglucosamine and for formation of sialyl Le^x or sialyl Le^a structures. Furthermore, the biosynthesis of cartilage keratan sulfate may be initiated by the core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase, since the keratan sulfate chain is extended from a branch present in core 2 structure in the same way as poly-*N*-acetylglucosamine (Dickenson et al., *Biochem. J.* 269:55-59 (1990), which is incorporated herein by reference). Keratan sulfate is absent in wild-type CHO cells, which do not express the core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase (Esko et al., *J. Biol. Chem.* 261:15725-15733 (1986), which is incorporated herein by reference). These structures are believed to be important for cellular recognition and matrix formation. The availability of the cDNA clone encoding the core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase will aid in understanding how the various carbohydrate structures are formed during differentiation and malignancy. Manipulation of the expression of the various carbohydrate structures by gene transfer and gene inactivation methods will help elucidate the various functions of these structures.

The present invention is directed to a method for transient expression cloning in CHO cells of cDNA sequences encoding proteins having enzymatic activity. Isolation of human core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase is provided as an example of the disclosed method. However, the method can be used to obtain cDNA sequences encoding other proteins having enzymatic activity.

For example, lectins and antibodies reactive with other specific oligosaccharide structures are available and can be used to screen for glycosyltransferase activity. Also, CHO cell lines that have defects in glycosylation have been isolated. These cell lines can be used to study the activity of the corresponding glycosyltransferase (Stanley, *Ann. Rev. Genet.* 18:525-552 (1984), which is incorporated herein by reference). CHO cell lines also have been selected for various defects in cellular metabolism, loss of expression of cell surface molecules and resistance to cytotoxic drugs (see, for example, Malmström and Krieger, *J. Biol. Chem.* 266:24025-24030 (1991); Yaron et al., *Cell* 64:841-848 (1991), which are incorporated herein by reference). The approach disclosed herein should allow isolation of cDNA sequences encoding the proteins involved in these various cellular functions.

As used herein, the terms "purified" and "isolated" mean that the molecule or compound is substantially free of contaminants normally associated with a native or natural environment. For example, a purified protein can be obtained from a number of methods. The naturally-occurring protein can be purified by any means known in the art, including, for example, by affinity purification with antibodies having specific reactivity with the protein. In this regard, anti-core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase antibodies can be used to substantially purify naturally-occurring core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase from human HL-60 promyelocytes.

Alternatively, a purified protein of the present invention can be obtained by well known recombinant methods, utilizing the nucleic acids disclosed herein, as described, for example, in Sambrook et al., *Molecular Cloning: A Laboratory Manual* 2d ed. (Cold Spring Harbor Laboratory 1989), which is incorporated herein by reference, and by the methods described in the Examples below. Furthermore, purified proteins can be synthesized by methods well known in the art.

As used herein, the phrase "substantially the sequence" includes the described nucleotide or amino acid sequence and sequences having one or more additions, deletions or substitutions that do not substantially affect the ability of the sequence to encode a protein having a desired functional activity. In addition, the phrase encompasses any additional sequence that hybridizes to the disclosed sequence under stringent hybridization sequences. Methods of hybridization are well known to those skilled in the art. For example, sequence modifications that do not substantially alter such activity are intended. Thus, a protein having substantially the amino acid sequence of Figure 5 (SEQ. ID. NO. 4) refers to core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase encoded by the cDNA described in Example IV, as well as proteins having

EP 0 590 747 A2

amino acid sequences that are modified but, nevertheless, retain the functions of core 2 β 1-6 *N*-acetylglucosaminyltransferase. One skilled in the art can readily determine such retention of function following the guidance set forth, for example, in Examples V and VI.

The present invention is further directed to active fragments of the human core 2 β 1-6 *N*-acetylglucosaminyltransferase protein. As used herein, an active fragment refers to portions of the protein that substantially retain the glycosyltransferase activity of the intact core 2 β 1-6 *N*-acetylglucosaminyltransferase protein. One skilled in the art can readily identify active fragments of proteins such as core 2 β 1-6 *N*-acetylglucosaminyltransferase by comparing the activities of a selected fragment with the intact protein following the guidance set forth in the Examples below.

As used herein, the term "glycosyltransferase activity" refers to the function of a glycosyltransferase to link sugar residues together through a glycosidic bond to create critical branches in oligosaccharides. Glycosyltransferase activity results in the specific transfer of a monosaccharide to an appropriate acceptor molecule, such that the acceptor molecule contains oligosaccharides having critical branches. One skilled in the art would understand the terms "enzymatic activity" and "catalytic activity" to generally refer to a function of certain proteins, such as the function of those proteins having glycosyltransferase activity.

As used herein, the term "acceptor molecule" refers to a molecule that is acted upon by a protein having enzymatic activity. For example, an acceptor molecule, such as leukosialin, as identified by the amino acid sequence of Figure 2 (SEQ. ID. NO. 2), accepts the transfer of a monosaccharide due to glycosyltransferase activity. An acceptor molecule, such as leukosialin, may already contain one or more sugar residues. The transfer of monosaccharides to an acceptor molecule, such as leukosialin, results in the formation of critical branches of oligosaccharides.

As used herein, the term "critical branches" refers to oligosaccharide structures formed by specific glycosyltransferase activity. Critical branches may be involved in various cellular functions, such as cell-cell recognition. The oligosaccharide structure of a critical branch can be determined using methods well known in the art, such as the method for determining the core 2 oligosaccharide structure, as described in Examples V and VI.

Relatedly, the invention also provides nucleic acids encoding the human core 2 β 1-6 *N*-acetylglucosaminyltransferase protein and leukosialin protein described above. The nucleic acids can be in the form of DNA, RNA or cDNA, such as the novel C2GnT cDNA of 2105 base pairs identified in Figure 5 (SEQ. ID. NO. 3) or the novel leukosialin cDNA identified in Figure 2 (SEQ. ID. NO. 1), for example. Such nucleic acids can also be chemically synthesized by methods known in the art, including, for example, the use of an automated nucleic acid synthesizer.

The nucleic acid can have substantially the nucleotide sequence of C2GnT, identified in Figure 5 (SEQ. ID. NO. 3), or leukosialin identified in Figure 2 (SEQ. ID. NO. 1). Portions of such nucleic acids that encode active fragments of the core 2 β 1-6 *N*-acetylglucosaminyltransferase protein or leukosialin protein of the present invention also are contemplated.

Nucleic acid probes capable of hybridizing to the nucleic acids of the present invention under reasonably stringent conditions can be prepared from the cloned sequences or by synthesizing oligonucleotides by methods known in the art. The probes can be labeled with markers according to methods known in the art and used to detect the nucleic acids of the present invention. Methods for detecting such nucleic acids can be accomplished by contacting the probe with a sample containing or suspected of containing the nucleic acid under hybridizing conditions, and detecting the hybridization of the probe to the nucleic acid.

The present invention is further directed to vectors containing the nucleic acids described above. The term "vector" includes vectors that are capable of expressing nucleic acid sequences operably linked to regulatory sequences capable of effecting their expression. Numerous cloning vectors are known in the art. Thus, the selection of an appropriate cloning vector is a matter of choice. In general, useful vectors for recombinant DNA are often plasmids, which refer to circular double stranded DNA loops such as pcDNA1 or pcDSF α . As used herein, "plasmid" and "vector" may be used interchangeably as the plasmid is a common form of a vector. However, the invention is intended to include other forms of expression vectors that serve equivalent functions.

Suitable host cells containing the vectors of the present invention are also provided. Host cells can be transformed with a vector and used to express the desired recombinant or fusion protein. Methods of recombinant expression in a variety of host cells, such as mammalian, yeast, insect or bacterial cells are widely known. For example, a nucleic acid encoding core 2 β 1-6 *N*-acetylglucosaminyltransferase or a nucleic acid encoding leukosialin can be transfected into cells using the calcium phosphate technique or other transfection methods, such as those described in Sambrook et al., *supra*, (1989).

EP 0 590 747 A2

Alternatively, nucleic acids can be introduced into cells by infection with a retrovirus carrying the gene or genes of interest. For example, the gene can be cloned into a plasmid containing retroviral long terminal repeat sequences, the C2Gnt DNA sequence or the leukosialin DNA sequence, and an antibiotic resistance gene for selection. The construct can then be transfected into a suitable cell line, such as PA12, which carries a packaging deficient provirus and expresses the necessary components for virus production, including synthesis of amphotrophic glycoproteins. The supernatant from these cells contain infectious virus, which can be used to infect the cells of interest.

Isolated recombinant polypeptides or proteins can be obtained by growing the described host cells under conditions that favor transcription and translation of the transfected nucleic acid. Recombinant proteins produced by the transfected host cells are isolated using methods set forth herein and by methods well known to those skilled in the art.

Also provided are antibodies having specific reactivity with the core 2 β 1-6 N-acetylglucosaminyltransferase protein or leukosialin protein of the present invention. Active fragments of antibodies, for example, Fab and Fab₂ fragments, having specific reactivity with such proteins are intended to fall within the definition of an "antibody." Antibodies exhibiting a titer of at least about 1.5×10^5 , as determined by ELISA, are useful in the present invention.

The antibodies of the invention can be produced by any method known in the art. For example, polyclonal and monoclonal antibodies can be produced by methods described in Harlow and Lane, Antibodies: A Laboratory Manual (Cold Spring Harbor 1988), which is incorporated herein by reference. The proteins, particularly core 2 β 1-6 N-acetylglucosaminyltransferase or leukosialin of the present invention can be used as immunogens to generate such antibodies. Altered antibodies, such as chimeric, humanized, CDR-grafted or bifunctional antibodies can also be produced by methods well known to those skilled in the art. Such antibodies can also be produced by hybridoma, chemical synthesis or recombinant methods described, for example, in Sambrook et al., *supra*, (1989).

The antibodies can be used for determining the presence or purification of the core 2 β 1-6 N-acetylglucosaminyltransferase protein or the leukosialin protein of the present invention. With respect to the detecting of such proteins, the antibodies can be used for *in vitro* or *in vivo* methods well known to those skilled in the art.

Finally, kits useful for carrying out the methods of the invention are also provided. The kits can contain a core 2 β 1-6 N-acetylglucosaminyltransferase protein, antibody or nucleic acid of the present invention and an ancillary reagent. Alternatively, the kit can contain a leukosialin protein, antibody or nucleic acid of the present invention and an ancillary reagent. An ancillary reagent may include diagnostic agents, signal detection systems, buffers, stabilizers, pharmaceutically acceptable carriers or other reagents and materials conventionally included in such kits.

A cDNA sequence encoding core 2 β 1-6 N-acetylglucosaminyltransferase was isolated and core 2 β 1-6 N-acetylglucosaminyltransferase activity was determined. This is the first report of transient expression cloning using CHO cells expressing polyoma large T antigen. The following examples are intended to illustrate but not limit the present invention.

EXAMPLE I

EXPRESSION CLONING IN COS-1 CELLS OF THE cDNA FOR THE PROTEIN CARRYING THE HEXASACCHARIDES

COS-1 cells were transfected with a cDNA library, pcDSR α -2F1, constructed from poly(A)⁺ RNA of activated T lymphocytes, which express the core 2 β 1-6 N-acetylglucosaminyltransferase (Yokota et al., Proc. Natl. Acad. Sci. USA 83:5894-5898 (1986); Piller et al., *supra*, (1988), which are incorporated herein by reference). COS-1 cells support replication of the pcDSR α constructs, which contain the SV40 replication origin. Transfected cells were selected by panning using monoclonal antibody T305, which recognizes sialylated branched hexasaccharides (Piller et al., *supra*, (1991); Saitoh et al., *supra*, (1991)). Methods referred to in this example are described in greater detail in the examples that follow.

Following several rounds of transfection, one plasmid, pcDSR α -leu, directing high expression of the T305 antigen was identified. The cloned cDNA insert was isolated and sequenced, then compared with other reported sequences. The newly isolated cDNA sequence was nearly identical to the sequence reported for leukosialin, except the 5'-flanking sequences were different (Pallant et al., Proc. Natl. Acad. Sci. USA 86:1328-1332 (1989), which is incorporated herein by reference).

Comparison of the cloned cDNA sequence with the genomic leukosialin DNA sequence revealed the start site of the cDNA sequence is located 259 bp upstream of the transcription start site of the previously

EP 0 590 747 A2

reported sequence (Figure 2; compare Exon 1' and Exon 1) (Shalley et al., *Biochem. J.* 270:569-576 (1990); Kudo and Fukuda, *J. Biol. Chem.* 266:8483-8489 (1991), which are incorporated herein by reference). A consensus splice site was identified at the exon-intron junction of the newly identified 122 bp exon 1' in pcDSR α -leu (Breathnach and Chambon, *Ann. Rev. Biochem.* 50:349-383 (1981), which is incorporated

5 herein by reference). This splice site is followed by the exon 2 sequence.

These results indicate the T305 antibody preferentially binds to branched hexasaccharides attached to leukosialin. Indeed, a small amount of the hexasaccharides (approximately 8% of the total) was detected in O-glycans isolated from control COS-1 cells. T305 binding is similar to anti-M and anti-N antibodies, which recognize both the glycan and polypeptide portions of erythrocyte glycoprotein, glycophorin (Sadler et al.,

10 *J. Biol. Chem.* 254: 2112-2119 (1979), which is incorporated herein by reference). These observations are consistent with reports that only leukosialin strongly reacted with T305 in Western blots of leukocyte cell extracts, even though leukocytes also express other glycoproteins, such as CD45, that must also contain the same hexasaccharides (Piller et al., *supra*, (1991); Saitoh et al., *supra*, (1991)).

15 EXAMPLE II

ESTABLISHMENT OF CHO CELL LINES THAT STABLY EXPRESS POLYOMA VIRUS LARGE T ANTIGEN AND LEUKOSIALIN

20 T305 preferentially binds to branched hexasaccharides attached to leukosialin. Such hexasaccharides are not present on the erythropoietin glycoprotein produced in CHO cells, although the glycoprotein does contain the precursor tetrasaccharide (Sasaki et al., *J. Biol. Chem.* 262:12059-12076 (1987), which is incorporated herein by reference). T305 antigen also is not detectable in CHO cells transiently transfected with pcDSR α -leu. In order to screen for the presence of a cDNA clone expressing core 2 β 1-6 N-acetylglucosaminyltransferase activity, a CHO cell line expressing both leukosialin and polyoma large T

25 antigen was established (see, for example, Heffernan and Dennis *Nucl. Acids Res.* 19:85-92 (1991), which is incorporated herein by reference).

Vectors: A plasmid vector, pPSVE1-PyE, which contains the polyoma virus early genes under the control of the SV40 early promoter, was constructed using a modification of the method of Muller et al., *Mol. Cell.* 30 *Biol.* 4:2406-2412 (1984), which is incorporated herein by reference. Plasmid pPSVE1 was prepared using pPSG4 (American Type Culture Collection 37337) and SV40 viral DNA (Bethesda Research Laboratories) essentially as described by Featherstone et al., *Nucl. Acids Res.* 12:7235-7249 (1984), which is incorporated herein by reference. Following EcoRI and HincII digestion of plasmid pPyLT-1 (American Type Culture Collection 41043), a DNA sequence containing the carboxy terminal coding region of polyoma virus

35 large T antigen was isolated. The HincII site was converted to an EcoRI site by blunt-end ligation of phosphorylated EcoRI linkers (Stratagene). Plasmid pPSVE1-PyE was generated by inserting the carboxy-terminal coding sequence for large T antigen into the unique EcoRI site of plasmid pPSVE1.

Plasmid pZIPNEO-leu was constructed by introducing the EcoRI fragment of PEER-3 cDNA, which contains the complete coding sequence for human leukosialin, into the unique EcoRI site of plasmid

40 pZIPNEO (Cepko et al., *Cell* 37:1053-1063 (1984), which is incorporated herein by reference). Plasmid structures were confirmed by restriction mapping and by sequencing the construction sites. pZIPNEO was kindly provided by Dr. Channing Der.

Transfection: CHODG44 cells were grown in 100 mm tissue culture plates. When the cells were 20% confluent, they were co-transfected with a 1:4 molar ratio of pZIPNEO-leu and pPSVE1-PyE using the calcium phosphate technique (Graham and van der Eb, *Virology* 52:456-467 (1973), which is incorporated

45 herein by reference). Transfected cells were isolated and maintained in medium containing 400 μ g/ml G-418 (active drug).

Leukosialin expression: The total pool of G418-resistant transfectants was enriched for human leukosialin expressing cells by a one-step panning procedure using anti-leukosialin antibodies and goat anti-rabbit IgG coated panning dishes (Sigma) (Carlsson and Fukuda *J. Biol. Chem.* 261:12779-12786 (1986), which is incorporated herein by reference). Clonal cell lines were obtained by limiting dilution. Six clonal cell lines expressing human leukosialin on the cell surface were identified by indirect immunofluorescence and isolated for further studies (Williams and Fukuda *J. Cell Biol.* 111:955-966 (1990), which is incorporated

55 herein by reference).

Polyoma virus-mediated replication: The ability of the six clonal cell lines to support polyoma virus large T antigen-mediated replication of plasmids was assessed by determining the methylation status of transfected plasmids containing a polyoma virus origin of replication (Muller et al., *supra*, 1984; Heffernan and Dennis, *supra*, 1991). Plasmid pGT/hCG contains a fused β 1-4 galactosyltransferase and human

EP 0 590 747 A2

chorionic gonadotropin α -chain DNA sequence inserted in plasmid pcDNA1, which contains a polyoma virus replication origin (Aoki et al., *Proc. Natl. Acad. Sci., USA* 89, 4319-4323 (1992), which is incorporated herein by reference).

Plasmid pGT/hCG was isolated from methylase-positive *E. coli* strain MC1081/P3 (Invitrogen), which methylates the adenine residues in the DpnI recognition site, "GATC". The methylated DpnI recognition site is susceptible to cleavage by DpnI. In contrast, the DpnI recognition site of plasmids replicated in mammalian cells is not methylated and, therefore, is resistant to DpnI digestion.

Methylated plasmid pGT/hCG was transfected by lipofection into each of the six selected clonal cell lines expressing leukosialin. After 64 hr, low molecular weight plasmid DNA was isolated from the cells using the method of Hirt, *J. Mol. Biol.* 26:365-369 (1967), which is incorporated herein by reference. Isolated plasmid DNA was digested with XhoI and DpnI (Stratagene), subjected to electrophoresis in a 1% agarose gel, and transferred to nylon membranes (Micron Separations Inc., MA).

A 0.4 kb SmaI fragment of the β 1-4 galactosyltransferase DNA sequence of pGT/hCG was radiolabeled with [32 P]dCTP using the random primer method (Feinberg and Vogelstein, *Anal. Biochem.* 132:6-13 (1983), which is incorporated herein by reference). Hybridization was performed using methods well-known to those skilled in the art (see, for example, Sambrook et al., *supra*, (1989)). Following hybridization, the membranes were washed several times, including a final high stringency wash in 0.1 x SSPE, 0.1% SDS for 1 hr at 65°C, then exposed to Kodak X-AR film at -70°C.

Four of the six clones tested supported replication of the pcDNA1-based plasmid, pGT/hCG (Fig. 3A., lanes 1, 3, 4 and 5). MOP-8 cells, a 3T3 cell line transformed by polyoma virus early genes (Muller et al., *supra*, (1984)), expresses endogenous core 2 β 1-6 N-acetylglucosaminyltransferase activity and was used as a control for the replication assay (Fig. 3B., lane 1). One clonal cell line that supported pGT/hCG replication, CHO-Py-leu (Fig. 3A., lane 5; Fig. 3B., lanes 2 and 3) and expressed a significant amount of leukosialin, was selected for further studies. pGT/hCG was kindly provided by Dr. Michiko Fukuda.

EXAMPLE III

ISOLATION OF A cDNA SEQUENCE DIRECTING EXPRESSION OF THE HEXASACCHARIDE ON LEUKOSIALIN

Poly(A)⁺ RNA was isolated from HL-60 promyelocytes, which contain a significant amount of the core 2 β 1-6N-acetylglucosaminyltransferase (Saitoh et al., *supra*, (1991)). A cDNA expression library, pcDNA1-HL-60, was prepared (Invitrogen) and the library was screened for clones directing the expression of the T305 antigen.

Plasmid DNA from the pcDNA1-HL-60 cDNA library was transfected into CHO-Py-leu cells using a modification of the lipofection procedure, described below (Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-7417 (1987), which is incorporated herein by reference). CHO-Py-leu cells were grown in 100 mm tissue culture plates. When the cells were 20% confluent, they were washed twice with Opti-MEM 1 (GIBCO). Fifty μ g of lipofectin reagent (Bethesda Research Laboratories) and 20 μ g of purified plasmid DNA were each diluted to 1.5 ml with Opti-MEM 1, then mixed and added to the cells. After incubation for 6 hr at 37°C, the medium was removed, 10 ml of complete medium was added and incubation was continued for 16 hr at 37°C. The medium was then replaced with 10 ml of fresh medium.

Following a 64 hr period to allow transient expression of the transfected plasmids, the cells were detached in PBS/5mM EDTA, pH7.4, for 30 min at 37°C, pooled, centrifuged and resuspended in cold PBS/10mM EDTA/5% fetal calf serum, pH7.4, containing a 1:200 dilution of ascites fluid containing T305 monoclonal antibody. The cells were incubated on ice for 1 hr, then washed in the same buffer and panned on dishes coated with goat anti-mouse IgG (Sigma) (Wysocki and Sato *Proc. Natl. Acad. Sci. USA* 75:2844-2848 (1978); Seed & Aruffo *Proc. Natl. Acad. Sci. USA* 84:3365-3369 (1987), which are incorporated herein by reference). T305 monoclonal antibody was kindly provided by Dr. R.I. Fox, Scripps Research Foundation, La Jolla, CA.

Plasmid DNA was recovered from adherent cells by the method of Hirt, *supra*, (1967), treated with DpnI to eliminate plasmids that had not replicated in transfected cells, and transformed into *E. coli* strain MC1081/P3. Plasmid DNA was then recovered and subjected to a second round of screening. *E. coli* transformants containing plasmids recovered from this second enrichment were plated to yield 8 pools of approximately 500 colonies each. Replica plates were prepared using methods well-known to those skilled in the art (see, for example, Sambrook et al., *supra*, (1989)).

The pooled plasmid DNA was prepared from replica plates and transfected into CHO-Py-leu cells. The transfectants were screened by panning. One plasmid pool was selected and subjected to three subsequent

EP 0 590 747 A2

rounds of selection. One plasmid, pcDNA1-C2GnT, which directed the expression of the T305 antigen, was isolated. CHO-Py-leu cells transfected with pcDNA1-C2GnT express the antigen recognized by T305, whereas CHO-Py-leu cells transfected with pcDNA1 are negative for T305 antigen (Fig. 4). These results show pcDNA1-C2GnT directs the expression of a new determinant on leukosialin that is recognized by T305 monoclonal antibody. This determinant is the branched hexasaccharide sequence, NeuNAc α 2 \rightarrow 3Gal β 1 \rightarrow 3-(NeuNAc α 2 \rightarrow 3Gal β 1 \rightarrow 4 GlcNAc β 1 \rightarrow 6)GalNAc.

EXAMPLE IV**CHARACTERIZATION OF C2GnT**

DNA sequence: The cDNA insert in plasmid pcDNA1-C2GnT was sequenced by the dideoxy chain termination method using Sequenase version 2 reagents (United States Biochemicals) (Sanger et al., *Proc. Natl. Acad. Sci. USA* 74:5463-5467 (1977), which is incorporated herein by reference). Both strands were sequenced using 17-mer synthetic oligonucleotides, which were synthesized as the sequence of the cDNA insert became known.

Plasmid pcDNA1-C2GnT contains a 2105 base pair insert (Fig. 5). The cDNA sequence (SEQ. ID. NO. 3) ends 1878 bp downstream of the putative translation start site. A polyadenylation signal is present at nucleotides 1694-1699. The significance of the large number of nucleotides between the polyadenylation signal and the beginning of the polyadenyl chain is not clear. However, this sequence is A/T rich.

Deduced amino acid sequence: The cDNA insert in plasmid pcDNA1-C2GnT encodes a single open reading frame in the sense orientation with respect to the pcDNA1 promoter (Fig. 5). The open reading frame encodes a putative 428 amino acid protein having a molecular mass of 49,790 daltons.

Hydropathy analysis indicates the predicted protein is a type II transmembrane molecule, as are all previously reported mammalian glycosyltransferases (Schachter, *supra*, (1991)). In this topology, a nine amino acid cytoplasmic NH₂-terminal segment is followed by a 23 amino acid transmembrane domain flanked by basic amino acid residues. The large COOH-terminus consists of the stem and catalytic domains and presumably faces the lumen of the Golgi complex.

The putative protein contains three potential N-glycosylation sites (Fig. 5, asterisks). However, one of these sites contains a proline residue adjacent to asparagine and is not likely utilized *in vivo*.

No matches were obtained when the C2GnT cDNA sequence and deduced amino acid sequence were compared with sequences listed in the PC/Gene 6.8 data bank. In particular, no homology was revealed between the deduced amino acid sequence of C2GnT and other glycosyltransferases, including N-acetylglucosaminyltransferase I (Sarkar et al., *Proc. Natl. Acad. Sci. USA* 88:234-238 (1991), which is incorporated herein by reference).

mRNA expression: Poly(A)⁺ RNA was prepared using a kit (Stratagene) and resolved by electrophoresis on a 1.2% agarose/2.2 M formaldehyde gel, and transferred to nylon membranes (Micro Separations Inc., MA) using methods well-known to those skilled in the art (see, for example, Sambrook et al., *supra*, (1989)). Membranes were probed using the EcoRI insert of pPROTA-C2GnT (see below) radiolabeled with [³²P]-dCTP by the random priming method (Feinberg and Vogelstein, *supra*, (1983). Hybridization was performed in buffers containing 50% formamide for 24 hr at 42°C (Sambrook et al., *supra*, (1989)). Following hybridization, filters were washed several times in 1xSSPE/0.1% SDS at room temperature and once in 0.1xSSPE/0.1% SDS at 42°C, then exposed to Kodak X-AR film at -70°C.

Fig. 6 compares the level of core 2 β 1 \rightarrow 6 N-acetylglucosaminyltransferase mRNA isolated from HL-60 promyelocytes, K562 erythroleukemia cells, and poorly metastatic SP and highly metastatic L4 colonic carcinoma cells. The major RNA species migrates at a size essentially identical to the -2.1 kb C2GnT cDNA sequence. The same result is observed for HL-60 cells and the two colonic cell lines, which apparently synthesize the hexasaccharides. In addition, two transcripts of -3.3 kb and 5.4 kb in size were detected in these cell lines. The two larger transcripts may result from differential usage of polyadenylation signals.

No hybridization occurred with poly(A)⁺ RNA isolated from K562 cells, which lack the hexasaccharide, but synthesize the tetrasaccharide (Carlsson et al., *supra*, (1986)), which is incorporated herein by reference. Similarly, no hybridization was observed for poly(A)⁺ RNA isolated from CHO-Py-leu cells (Fig. 6, lane 1).

EP 0 590 747 A2

EXAMPLE V**EXPRESSION OF ENZYMATICALLY ACTIVE β 1-6 N-ACETYLGLUCOSAMINYLTRANSFERASE**

5 In order to confirm that C2GnT cDNA encodes for core 2 β 1-6 N-acetylglucosaminyltransferase, enzymatic activity was examined in CHO-Py-leu cells transfected with pcDNA1 or pcDNA1-C2GnT. Following a 64 hr period to allow transient expression, cell lysates were prepared and core 2 β 1-6 N-acetylglucosaminyltransferase activity was measured.

10 N-acetylglucosaminyltransferase assays were performed essentially as described by Saitoh et al., *supra*, (1991), Yousefi et al., *supra*, (1991), and Lee et al., *J. Biol. Chem.* 265:20476-20487 (1990), which is incorporated herein by reference. Each reaction contained 50 mM MES, pH7.0, 0.5 μ Ci of UDP-[3 H]GlcNAc in 1 mM UDP-GlcNAc, 0.1 M GlcNAc, 10 mM Na₂EDTA, 1mM of acceptor and 25 μ l of either cell lysate, cell supernatant or IgG-Sepharose matrix in a total reaction volume of 50 μ l.

15 Reactions were incubated for 1 hr at 37 °C, then processed by C18 Sep-Pak chromatography (Waters) (Palcic et al., *J. Biol. Chem.* 265:8759-8769 (1990), which is incorporated herein by reference). Core 2 and core 4 β 1-6 N-acetylglucosaminyltransferase were assayed using the acceptors p-nitrophenyl Gal β 1-3GalNAc and p-nitrophenyl GlcNAc β 1-3GalNAc, respectively (Toronto Research Chemicals).

UDP-GlcNAc: α -Man β 1-6 N-acetylglucosaminyltransferase(V) was assayed using the acceptor GlcNAc β 1-2Man α 1-6Glc- β -O-(CH₂)₆CH₃. The blood group I enzyme, UDP-GlcNAc:GlcNAc β 1-3Gal β 1-4GlcNAc (GlcNAc to Gal) β 1-6 N-acetylglucosaminyltransferase, was assayed using GlcNAc β 1-3Gal β 1-4GlcNAc β 1-6Man α 1-6Man β 1-O-(CH₂)₆COOCH₃ or Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc β 1-3Gal β 1-4GlcNAc β 1-O-(CH₂)₆CH₃ as acceptors (Gu et al., *J. Biol. Chem.* 267:2994-2999 (1992), which is incorporated herein by reference). Synthetic acceptors were kindly provided by Dr. Olé Hindsgaul, University of Alberta, Canada.

25 Results of these assays are shown in Table I. Assuming transfection efficiency of the cells is approximately 20-30%, the level of enzymatic activity directed by cells transfected with pcDNA1-C2GnT is roughly equivalent to the level observed in HL-60 cells.

30

35

40

45

50

55

EP 0 590 747 A2

TABLE I

Core 2 β 1 \rightarrow 6 N-acetylglucosaminyltransferase activity in CHO-Py-leu cell extracts transfected with pcDNA1 or pcDNA1-C2GnT.	
Vector	Core 2 β 1 \rightarrow 6 GlcNAc transferase activity (pmol/mg of protein/hr)
pcDNA1	n.d.
pcDNA1-C2GnT	784

CHO-Py-leu cells were transfected with pcDNA1 or pcDNA1-C2GnT, as described in the specification. Endogenous activity was measured in the absence of acceptor and subtracted from values determined in the presence of added acceptor. Gal β 1 \rightarrow 3GalNAc α -p-nitrophenyl was used as an acceptor. n.d. = not detectable. For comparison, the core 2 β 1 \rightarrow 6 N-acetylglucosaminyltransferase activity measured in HL-60 cells under identical conditions was 3228 pmol/mg of protein per hr.

EP 0 590 747 A2

In order to unequivocally establish that C2GnT cDNA sequence encodes core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase, plasmid, pPROTA-C2GnT was constructed containing the DNA sequence encoding the putative catalytic domain of core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase fused in frame with the signal peptide and IgG binding domain of *S. aureus* protein A (Fig. 7). The putative catalytic domain is contained in a 1330 bp fragment of the C2GnT cDNA that encodes amino acid residues 38 to 428. Plasmid pPROTA was kindly provided by Dr. John B. Lowe.

The polymerase chain reaction (PCR) was used to insert EcoRI recognition sites on either side of the 1330 bp sequence in pcDNA1-C2GnT DNA. PCR was performed using the synthetic oligonucleotide primers 5'-TTTGAATTCCTGAAATTTGTAAGTGTCAGACAC-3' (SEQ. ID. NO. 5) and 5'-TTTGAATTCGCAGAAACCATGCAGCTTCTCTGA-3' (SEQ. ID. NO. 6) (EcoRI recognition sites underlined). The EcoRI sites allowed direct, in-frame insertion of the fragment into the unique EcoRI site of plasmid pPROTA (Sanchez-Lopez et al., *J. Biol. Chem.* 263:11892-11899 (1988), which is incorporated herein by reference).

The nucleotide sequence of the insert as well as the proper orientation were confirmed by DNA sequencing using the primers described above for cDNA sequencing. Plasmid pPROTA-C2GnT allows secretion of the fusion protein from transfected cells and binding of the secreted fusion protein by insolubilized immunoglobulins.

Either pPROTA or pPROTA-C2GnT was transfected into COS-1 cells. Following a 64 hr period to allow transient expression, cell supernatants were collected (Kukowska-Latallo et al., *supra*, (1990)). Cell supernatants were cleared by centrifugation, adjusted to 0.05% Tween 20 and either assayed directly for core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase activity or used in IgG-Sepharose (Pharmacia) binding studies. For the latter assay, supernatants (10 ml) were incubated batchwise with approximately 300 μ l of IgG-Sepharose for 4 hr at 4°C. The matrices were then extensively washed and used directly for glycosyltransferase assays.

No core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase activity was detected in the medium of COS-1 cells transfected with the control plasmid, pPROTA. Similarly, no enzymatic activity was associated with IgG-Sepharose beads. In contrast, a significant level of core 2 β 1 \rightarrow 6 *N*-acetylglucosaminyltransferase activity was detected in the medium of COS-1 cells transfected with pPROTA-C2GnT. The activity also associated with the IgG-Sepharose beads (Table II). No activity was detected in the supernatant following incubation of the supernatant with IgG-Sepharose.

EP 0 590 747 A2

TABLE II

Determination of Enzymatic Activities Directed by
pPROTA-C2GnT.

Acceptors and linkages formed	Radioactivity (cpm) with (+) and without (-) acceptor	
	-	+
<i>GlcNAcB1</i> 6 GalB1→3GalNAc (core 2-GnT)	109	1048
<i>GlcNAcB1</i> 6 GlcNAcB1→3GalNAc (core 4-GnT)	111	113
<i>GlcNAcB1</i> 6 GlcNAcB1→2Man (GnTV)	118	115
<i>GlcNAcB1</i> 6 GlcNAcB1→3Gal (I-GnT)	111	113
<i>GlcNAcB1</i> 6 GalB1→4GlcNAcB1→3Gal (I-GnT)	99	96

COS-1 cells were transfected with pPROTA-C2GnT and the conditioned media were incubated with IgG-Sepharose. The proteins bound to the IgG-Sepharose were assayed for B1→6 *N*-acetylglucosaminyltransferase activity by using appropriate acceptors. The linkages formed are indicated by italics. Similar results were obtained in three independent experiments.

EP 0 590 747 A2

EXAMPLE VI**DETERMINATION OF C2GnT SPECIFICITY**

5 Four types of $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase linkages have been reported, including core 2 and core 4 in *O*-glycans, I-antigen and a branch attached to mannose that forms tetraantennary *N*-glycans (see Table II). In order to determine whether these different structures are also synthesized by the cloned C2GnT cDNA sequence, enzymatic activity was determined using five different acceptors.

10 As shown in Table II, the fusion protein was only active with the acceptor for core 2 formation. The same was true when the formation of $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyl linkage to internal galactose residues was examined (Table II, see structure at bottom). This result precludes the likelihood that the enzyme encoded by the C2GnT cDNA sequence may add *N*-acetylglucosamine to a non-reducing terminal galactose. The HL-60 core 2 $\beta 1 \rightarrow 8$ *N*-acetylglucosaminyltransferase is exclusively responsible for the formation of the GlcNAc $\beta 1 \rightarrow 6$ branch on Gal $\beta 1 \rightarrow 3$ GalNAc.

15 Although the invention has been described with reference to the disclosed embodiments, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

Lowe et al., Cell 63:475-484 (1990)

Brandley et al., Cell 63:861-863 (1990)

20 Phillips et al., Science 250:1130-1132 (1990)

Walz et al., Science 250:1132-1135 (1990)

Higgins et al., J. Biol. Chem. 266:6280-6290 (1991)

Schachter, Biochem. Cell Biol. 64:163-181 (1986)

EP 0 590 747 A2

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: La Jolla Cancer Research Foundation
(B) STREET: 10901 North Torrey Pines Road
(C) CITY: La Jolla
(D) STATE: California
(E) COUNTRY: U.S.A.
(F) POSTAL CODE (ZIP): 92037

(ii) TITLE OF INVENTION: A NOVEL BETA1-6
N-ACETYLGLUCOSAMINYLTRANSFERASE, ITS ACCEPTOR MOLECULE,
LEUKOSIALIN AND A METHOD FOR CLONING PROTEINS HAVING
ENZYMATIC ACTIVITY

(iii) NUMBER OF SEQUENCES: 8

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 900 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: both
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 841..900

(ix) FEATURE:

(A) NAME/KEY: exon
(B) LOCATION: 91..192
(D) OTHER INFORMATION: /note= 'EXON 1' IS LOCATED IN BOTH
GENOMIC AND cDNA. IN THE cDNA EXON 1' IS
IMMEDIATELY FOLLOWED BY EXON 2.'

(ix) FEATURE:

(A) NAME/KEY: exon
(B) LOCATION: 359..428
(D) OTHER INFORMATION: /note= 'EXON 1 IS LOCATED IN
GENOMIC DNA'

(ix) FEATURE:

(A) NAME/KEY: intron
(B) LOCATION: 193..806
(D) OTHER INFORMATION: /note= 'THIS SEGMENT OF NUCLEIC
ACID CONSTITUTES INTRON SEQUENCE OF THE cDNA'

EP 0 590 747 A2

(ix) FEATURE:

(A) NAME/KEY: exon

(B) LOCATION: 807..900

(D) OTHER INFORMATION: /note= "EXON 2 IS LOCATED IN BOTH
GENOMIC AND cDNA. IN THE cDNA EXON 2 IMMEDIATELY
FOLLOWS EXON 1."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

10 TTGGGGACCA CAAATGCAAA GGAAACCACC CTCCCCTCCG ACCTCCTCCT CTGCACCCTT 60
 GAGTTCTCAG GCTCACATT CCACCACCCA CCTCTGAGCC CAGCCCTCCC TAGCATCACC 120
 ACTTCCATCC CATTCCTCAG CCAAGAGCCA GGAATCCTGA TTCCAGATCC CAGGCTTCCC 180
 TGCCTCCCTC AGGTGAGCCC CAGACCCCCA GGCACCCCGC TGGCGCCTGA AGGAGCAGGT 240
 15 GATGCTGCTG TCTTCGCCCC GCAGCTGTGG GAGCAGGCGG GTGGGGCAGG ATGGAGGGGT 300
 GGGTGGGGTG GGTGGAGCCA GGGCCCACTT CCTTTCCCCT TGGGGCCCTG TCCTTCCCAG 360
 TCTTGCCCCA GCCTCGGGAG GTGGTGGAGT GACCTGGGCC CAGTGCTGCG TCCTTATCAG 420
 20 CCCAGCCGGT AAGAGGGTGA GACTTGGTGG GGTAGGGGCC TCAGTGGGCC TGGGAATGTG 480
 CCTGTGGCTT GAAAAGACTC TGACAGGTTA TGATGGGAAG AGATTGGGAG CCATTGGGCT 540
 GCACAGGGTC AGGGAAGGCC AGGAGGGGCT GGTCACTGCT GGAATCTAAG CTGCTGAGGC 600
 25 TGGAGGGAGC CTCAGGATGG GGCTGATGGG GGAGCTGCCA GCATCTGTTC CTCTGTCAAT 660
 TCTGATAACA GTAAAAGCCA GCATGGAAAA AACCGTAAAA CCGCAGGTTG GGCCTGGCCG 720
 TTGGCAGGGA AGTGGGCAGA GGGGAGGCCG GCCCAGGTCC TCCGGCAACT CCCGCGTGT 780
 CTGCTTCTCG GGCTGCCCAC CTGCAGGTCC CAGCTCTTGC TCCTGCCTGT TTGCCTGGAA 840
 30 ATG GCC ACG CTT CTC CTT CTC CTT GGG GTG CTG GTG GTA AGC CCA GAC. 888
 Met Ala Thr Leu Leu Leu Leu Gly Val Leu Val Val Ser Pro Asp
 1 5 10 15
 GCT CTG GGG AGC
 35 Ala Leu Gly Ser 900
 20

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

40 Met Ala Thr Leu Leu Leu Leu Gly Val Leu Val Val Ser Pro Asp
 1 5 10 15
 50 Ala Leu Gly Ser 20

55

EP 0 590 747 A2

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2105 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: both
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 220..1504

(ix) FEATURE:

- (A) NAME/KEY: polyA signal
 (B) LOCATION: 1913..1918

(ix) FEATURE:

- (A) NAME/KEY: misc_signal
 (B) LOCATION: 248..314
 (D) OTHER INFORMATION: /standard_name=
 "SIGNAL/MEMBRANE-ANCHORING DOMAIN"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GTGAAGTGCT CAGAATGGGC CAGGATGTCA CCTGGAATCA GCACTAAGTG ATTCAGACTT	60
TCCTTACTTT TAAATGTGCT GCTCTTCATT TCAAGATGCC GTTGCACTC TGATAAATGC	120
AAACTGACAA CCTTCAAGGC CAGGACGGAG GGAAAATCAT TGGTGCTTGG AGCATAGAAG	180
ACTGCCCTTC ACAAAGGAAA TCCCTGATTG TTGTTTGAA ATG CTG AGG ACG TTG	234
Met Leu Arg Thr Leu	5
CTG CGA AGG AGA CTT TTT TCT TAT CCC ACC AAA TAC TAC TTT ATG GTT	282
Leu Arg Arg Arg Leu Phe Ser Tyr Pro Thr Lys Tyr Tyr Phe Met Val	20
CTT GTT TTA TCC CTA ATC ACC TTC TCC GTT TTA AGG ATT CAT CAA AAG	330
Leu Val Leu Ser Leu Ile Thr Phe Ser Val Leu Arg Ile His Gln Lys	35
CCT GAA TTT GTA AGT GTC AGA CAC TTG GAG CTT GCT GGG GAG AAT CCT	378
Pro Glu Phe Val Ser Val Arg His Leu Glu Leu Ala Gly Glu Asn Pro	50
AGT AGT GAT ATT AAT TGC ACC AAA GTT TTA CAG GGT GAT GTA AAT GAA	426
Ser Ser Asp Ile Asn Cys Thr Lys Val Leu Gln Gly Asp Val Asn Glu	65
ATC CAA AAG GTA AAG CTT GAG ATC CTA ACA GTG AAA TTT AAA AAG CGC	474
Ile Gln Lys Val Lys Leu Glu Ile Leu Thr Val Lys Phe Lys Lys Arg	85
CCT CGG TGG ACA CCT GAC GAC TAT ATA AAC ATG ACC AGT GAG TGT TCT	522
Pro Arg Trp Thr Pro Asp Asp Tyr Ile Asn Met Thr Ser Asp Cys Ser	100

EP 0 590 747 A2

	TCT	TTC	ATC	AAG	AGA	CGC	AAA	TAT	ATT	GTA	GAA	CCC	CTT	AGT	AAA	GAA	570
	Ser	Phe	Ile	Lys	Arg	Arg	Lys	Tyr	Ile	Val	Glu	Pro	Leu	Ser	Lys	Glu	
				105					110					115			
5	GAG	CGC	CAG	TTT	CCA	ATA	GCA	TAT	TCT	ATA	GTG	GTT	CAT	CAC	AAG	ATT	618
	Glu	Ala	Glu	Phe	Pro	Ile	Ala	Tyr	Ser	Ile	Val	Val	His	His	Lys	Ile	
			120					125					130				
	GAA	ATG	CTT	GAC	AGG	CTG	CTG	AGG	GCC	ATC	TAT	ATG	CCT	CAG	AAT	TTC	666
10	Glu	Met	Leu	Asp	Arg	Leu	Leu	Arg	Ala	Ile	Tyr	Met	Pro	Gln	Asn	Phe	
		135					140					145					
	TAT	TGC	GTT	CAT	GTG	GAC	ACA	AAA	TCC	GAG	GAT	TCC	TAT	TTA	GCT	GCA	714
	Tyr	Cys	Val	His	Val	Asp	Thr	Lys	Ser	Glu	Asp	Ser	Tyr	Leu	Ala	Ala	
		150				155				160					165		
15	GTG	ATG	GGC	ATC	GCT	TCC	TGT	TTT	AGT	AAT	GTC	TTT	GTG	GCC	AGC	CGA	762
	Val	Met	Gly	Ile	Ala	Ser	Cys	Phe	Ser	Asn	Val	Phe	Val	Ala	Ser	Arg	
				170						175					180		
	TTG	GAG	AGT	GTG	GTT	TAT	GCA	TCG	TGG	AGC	CGG	GTT	CAG	GCT	GAC	CTC	810
	Leu	Glu	Ser	Val	Val	Tyr	Ala	Ser	Trp	Ser	Arg	Val	Gln	Ala	Asp	Leu	
				185					190					195			
20	AAC	TGC	ATG	AAG	GAT	CTC	TAT	GCA	ATG	AGT	GCA	AAC	TGG	AAG	TAC	TTG	858
	Asn	Cys	Met	Lys	Asp	Leu	Tyr	Ala	Met	Ser	Ala	Asn	Trp	Lys	Tyr	Leu	
			200					205					210				
	ATA	AAT	CTT	TGT	GGT	ATG	GAT	TTT	CCC	ATT	AAA	ACC	AAC	CTA	GAA	ATT	906
25	Ile	Asn	Leu	Cys	Gly	Met	Asp	Phe	Pro	Ile	Lys	Thr	Asn	Leu	Glu	Ile	
		215					220					225					
	GTC	AGG	AAG	CTC	AAG	TTG	TTA	ATG	GGA	GAA	AAC	AAC	CTG	GAA	ACG	GAG	954
	Val	Arg	Lys	Leu	Lys	Leu	Leu	Met	Gly	Glu	Asn	Asn	Leu	Glu	Thr	Glu	
		230				235					240				245		
30	AGG	ATG	CCA	TCC	CAT	AAA	GAA	GAA	AGG	TGG	AAG	AAG	CGG	TAT	GAG	GTC	1002
	Arg	Met	Pro	Ser	His	Lys	Glu	Glu	Arg	Trp	Lys	Lys	Arg	Tyr	Glu	Val	
				250						255					260		
	GTT	AAT	GGA	AAG	CTG	ACA	AAC	ACA	GGG	ACT	GTC	AAA	ATG	CTT	CCT	CCA	1050
	Val	Asn	Gly	Lys	Leu	Thr	Asn	Thr	Gly	Thr	Val	Lys	Met	Leu	Pro	Pro	
				265					270					275			
35	CTC	GAA	ACA	CCT	CTC	TTT	TCT	GGC	AGT	GCC	TAC	TTC	GTG	GTC	AGT	AGG	1098
	Leu	Glu	Thr	Pro	Leu	Phe	Ser	Gly	Ser	Ala	Tyr	Phe	Val	Val	Ser	Arg	
			280					285					290				
40	GAG	TAT	GTG	GGG	TAT	GTA	CTA	CAG	AAT	GAA	AAA	ATC	CAA	AAG	TTG	ATG	1146
	Glu	Tyr	Val	Gly	Tyr	Val	Leu	Gln	Asn	Glu	Lys	Ile	Gln	Lys	Leu	Met	
		295					300					305					
	GAG	TGG	GCA	CAA	GAC	ACA	TAC	AGC	CCT	GAT	GAG	TAT	CTC	TGG	GCC	ACC	1194
	Glu	Trp	Ala	Gln	Asp	Thr	Tyr	Ser	Pro	Asp	Glu	Tyr	Leu	Trp	Ala	Thr	
		310				315					320				325		
45	ATC	CAA	AGG	ATT	CCT	GAA	GTC	CCG	GGC	TCA	CTC	CCT	GCC	AGC	CAT	AAG	1242
	Ile	Gln	Arg	Ile	Pro	Glu	Val	Pro	Gly	Ser	Leu	Pro	Ala	Ser	His	Lys	
				330					335						340		
50	TAT	GAT	CTA	TCT	GAC	ATG	CAA	GCA	GTT	GCC	AGG	TTT	GTC	AAG	TGG	CAG	1290
	Tyr	Asp	Leu	Ser	Asp	Met	Gln	Ala	Val	Ala	Arg	Phe	Val	Lys	Trp	Gln	
				345					350					355			

65

EP 0 590 747 A2

TAC TTT GAG GGT GAT GTT TCC AAG GGT GCT CCC TAC CCG CCC TGC GAT 1338
 Tyr Phe Glu Gly Asp Val Ser Lys Gly Ala Pro Tyr Pro Pro Cys Asp
 360 365 370
 5 GGA GTC CAT GTG CGC TCA GTG TGC ATT TTC GGA GCT GGT GAC TTG AAC 1386
 Gly Val His Val Arg Ser Val Cys Ile Phe Gly Ala Gly Asp Leu Asn
 375 380 385
 10 TGG ATG CTG CGC AAA CAC CAC TTG TTT GCC AAT AAG TTT GAC GTG GAT 1434
 Trp Met Leu Arg Lys His His Leu Phe Ala Asn Lys Phe Asp Val Asp
 390 395 400 405
 GTT GAC CTC TTT GCC ATC CAG TGT TTG GAT GAG CAT TTG AGA CAC AAA 1482
 Val Asp Leu Phe Ala Ile Gln Cys Leu Asp Glu His Leu Arg His Lys
 410 415 420
 15 GCT TTG CAG ACA TTA AAA CAC T GACCATTACG GGCAATTTTA TGAACAAGAA 1534
 Ala Leu Glu Thr Leu Lys His
 425
 GAAGGATACA CAAAACGTAC CTTATCTGTT TCCCCTTCCT TGTGAGCGTC GGAAGATGG 1594
 20 TATGAAGTCC TCTTTGGGGC AGGCACTCTA GTAGATCTTC TTGTCAGAGA AGCTGCATGG 1654
 TTTCTGCAGA GCACAGTTAG CTAGAAAGGT GATACCATTA AATGTTTCATC TAGAGTTAAT 1714
 AGTGGGAGGA GTAAAGGTAG CCTTGAGGCC AGAGCAGGTA GCAAGGCATT GTGGAAGAG 1774
 GGGACCAGCG TGGCTGGGGA AGAGGCCGAT GCATAAAGTC AGCCTGTTCC AAGTGCCTCAG 1834
 25 GGACTTAGCA AAATGAGAAG ATGTGACCTG TGCCAAACT ATTTTGAGAA TTTTAAATGT 1894
 GACCATTTTT CTGCTATGAA TAACTTACA GCAACAAATA ATCAAAGATA CAATTAATCT 1954
 GATATTATAT TTGTTGAAAT AGAAATTIGA TTGTACTATA AATGATTTTT GTAAATAATT 2014
 30 TATATTCTGC TCTAATACTG TACTGTGTAG TGTGTCTCCG TATGTCATCT CAGGGAGCTT 2074
 AAAATGGGCT TGATTTAACA TTGAAAAAA A 2105

(2) INFORMATION FOR SEQ ID NO:4:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 428 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 40 (ii) MOLECULE TYPE: protein
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
 Met Leu Arg Thr Leu Leu Arg Arg Arg Leu Phe Ser Tyr Pro Thr Lys
 1 5 10 15
 45 Tyr Tyr Phe Met Val Leu Val Leu Ser Leu Ile Thr Phe Ser Val Leu
 20 25 30
 Arg Ile His Gln Lys Pro Glu Phe Val Ser Val Arg His Leu Glu Leu
 35 40 45
 50 Ala Gly Glu Asn Pro Ser Ser Asp Ile Asn Cys Thr Lys Val Leu Gln
 50 55 60

55

EP 0 590 747 A2

Gly Asp Val Asn Glu Ile Gln Lys Val Lys Leu Glu Ile Leu Thr Val
 65 70 75 80
 6 Lys Phe Lys Lys Arg Pro Arg Trp Thr Pro Asp Asp Tyr Ile Asn Met
 85 90 95
 Thr Ser Asp Cys Ser Ser Phe Ile Lys Arg Arg Lys Tyr Ile Val Glu
 100 105 110
 10 Pro Leu Ser Lys Glu Glu Ala Glu Phe Pro Ile Ala Tyr Ser Ile Val
 115 120 125
 Val His His Lys Ile Glu Met Leu Asp Arg Leu Leu Arg Ala Ile Tyr
 130 135 140
 15 Met Pro Gln Asn Phe Tyr Cys Val His Val Asp Thr Lys Ser Glu Asp
 145 150 155 160
 Ser Tyr Leu Ala Ala Val Met Gly Ile Ala Ser Cys Phe Ser Asn Val
 165 170 175
 20 Phe Val Ala Ser Arg Leu Glu Ser Val Val Tyr Ala Ser Trp Ser Arg
 180 185 190
 Val Gln Ala Asp Leu Asn Cys Met Lys Asp Leu Tyr Ala Met Ser Ala
 195 200 205
 25 Asn Trp Lys Tyr Leu Ile Asn Leu Cys Gly Met Asp Phe Pro Ile Lys
 210 215 220
 Thr Asn Leu Glu Ile Val Arg Lys Leu Lys Leu Leu Met Gly Glu Asn
 225 230 235 240
 30 Asn Leu Glu Thr Glu Arg Met Pro Ser His Lys Glu Glu Arg Trp Lys
 245 250 255
 Lys Arg Tyr Glu Val Val Asn Gly Lys Leu Thr Asn Thr Gly Thr Val
 260 265 270
 35 Lys Met Leu Pro Pro Leu Glu Thr Pro Leu Phe Ser Gly Ser Ala Tyr
 275 280 285
 Phe Val Val Ser Arg Glu Tyr Val Gly Tyr Val Leu Gln Asn Glu Lys
 290 295 300
 40 Ile Gln Lys Leu Met Glu Trp Ala Gln Asp Thr Tyr Ser Pro Asp Glu
 305 310 315 320
 Tyr Leu Trp Ala Thr Ile Gln Arg Ile Pro Glu Val Pro Gly Ser Leu
 325 330 335
 45 Pro Ala Ser His Lys Tyr Asp Leu Ser Asp Met Gln Ala Val Ala Arg
 340 345 350
 Phe Val Lys Trp Gln Tyr Phe Glu Gly Asp Val Ser Lys Gly Ala Pro
 355 360 365
 50 Tyr Pro Pro Cys Asp Gly Val His Val Arg Ser Val Cys Ile Phe Gly
 370 375 380
 Ala Gly Asp Leu Asn Trp Met Leu Arg Lys His His Leu Phe Ala Asn
 385 390 395 400

55

EP 0 590 747 A2

Lys Phe Asp Val Asp Val Asp Leu Phe Ala Ile Gln Cys Leu Asp Glu
405 410 415

His Leu Arg His Lys Ala Leu Glu Thr Leu Lys His
420 425

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TTTGAATTCC CCTGAATTTC TAAGTGTACG ACAC

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TTTGAATTCC CAGAAACCAT GCAGCTTCTC TGA

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

- (A) NAME/KEY: CDS
(B) LOCATION: 1..15
(D) OTHER INFORMATION: /note= "PROTEIN A - C2GNT FUSION
PROTEIN"

EP 0 590 747 A2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

5 GGG AAT TCC CCT GAA
 Gly Asn Ser Pro Glu
 1 5

15

10 (2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

20 Gly Asn Ser Pro Glu
 1 5

Claims

- 25 1. A purified human protein or an active fragment thereof having $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase activity.
- 30 2. The purified protein of claim 1, wherein said activity is that of UDP-GlcNAc:Gal $\beta 1 \rightarrow 3$ GalNAc (GlcNAc to GalNAc) $\beta 1 \rightarrow 6$ *N*-acetylglucosaminyltransferase.
3. The purified protein of claim 2, wherein said protein has a relative molecular weight of about 50 kD.
4. An isolated nucleic acid encoding the human protein or active fragment thereof of claim 1.
- 35 5. A vector containing the nucleic acid of claim 4.
6. The vector of claim 5, wherein said vector is a plasmid.
- 40 7. The vector of claim 5, wherein said vector is pcDNA1-C2GnT.
8. A host cell containing the vector of claim 5.
- 45 9. A purified human protein or a fragment thereof that is an acceptor molecule, said acceptor molecule being acted upon by the protein of claim 2 having activity which exclusively forms core 2 oligosaccharide structures in *O*-glycans.
10. The acceptor molecule of claim 9, wherein said acceptor molecule is leukosialin, CD43.
- 50 11. An isolated nucleic acid encoding the acceptor molecule of claim 9.
12. A vector containing the nucleic acid of claim 11.
13. The vector of claim 12, wherein said vector is a plasmid.
- 55 14. The vector of claim 12, wherein said vector is pcDSR α -leu.
15. A host cell containing the vector of claim 12.

EP 0 590 747 A2

16. A method of obtaining from a cell line, which does not normally contain a protein having catalytic activity or an acceptor molecule for said protein, a nucleic acid encoding said protein having catalytic activity comprising:

- a. transfecting said cell line with a DNA sequence encoding the acceptor molecule, wherein the acceptor molecule is stably expressed in the cell line;
- b. transfecting said cell line with a cDNA library containing said nucleic acid in a vector, wherein proteins encoded by the transfected cDNA are transiently expressed;
- c. screening the transfected cells for expression of said protein having catalytic activity; and
- d. isolating the nucleic acid encoding the protein having catalytic activity.

17. The vector of claim 16, wherein said vector replicates in the transfected cell line.

18. The vector in claim 17, wherein said vector is a plasmid.

19. The vector of claim 16, wherein said vector contains a viral replication origin.

20. The vector of claim 19, wherein said replication origin is the polyoma virus replication origin.

21. The cell line of claim 16, wherein said cell line supports replication of a vector.


22. The cell line of claim 16, wherein said cell line expresses polyoma virus large T antigen.

23. The cell line of claim 16, wherein said cell line is the Chinese hamster ovary cell line.

24. The cell line of claim 23, wherein said cell line is CHO-Py-leu.

25. A method of isolating a polypeptide having catalytic activity that forms core 2 oligosaccharide structures in O-glycans, said method comprising growing the host cell of claim 8 under conditions which favor expression of a nucleic acid encoding said polypeptide, and isolating said polypeptide so produced.

EP 0 590 747 A2



EP 0 590 747 A2

TTGGGACCACAAATGCAAAGGAACACCCTCCCTCCACCTCCTCTCGACCCCTT -299
 GAGTTCTCAGGCTCACATTCCACCACCCACCTCTGAGCCAGCCCTCCCTAGCATCACC -239
ACTTCCATCCCATTCCTCAGCCAAGAGCCAGGAATCCIGATTCCAGATCCACGCTTCCC -179
TGCCCTCCCTCAGGTGAGCCCCAGACCCCCAGGCACCCCGCTGGCCCCCTGAAGGAGCAGGT -119
 GATGGTGTGCTTTCGCCCAGCAGCTGTGGGAGCAGGCGGGTGGGGCAGGATGGAGGGGT -59
 GGGTGGGGTGGGTGGAGCCAGGGCCACATTCTTCCCTTGGGGCCCTGTCTTCCQAG 2
TCCTGCCCCAGCCTCGGGAGGTGGTGGAGTGACCTGGCCCCCAGTGCCTCTTATCAG 62
CCGAGCCGGTAAGAGGGTGAGACTTGGTGGGGTAGGGCCCTCAGTGGGCTGGGAATGTG 122
 CCTGTGGCTTGAAAAGACTCTGACAGGTTATGATGGGAAGAGATTGGGAGCCATTGGGCT 182
 GCACAGGGTCAGGGAAGGCCAGGAGGGCTGGTCACTGCTGGAATCTAAGCTGCTGAGGC 242
 TGGAGGGAGCCTCAGGATGGGGCTGATGGGGGAGCTGCCAGCATCTGTCTCTGTCTCATY 302
 TCTGATAACAGTAAAGCCAGCATGGAAAAAACCGTTAAACCGCAGGTTGGGCTGGCCG 362
 TTGGCAGGGAAGTGGGCAGAGGGGAGGCCCGGCCAGGTCTCCGGCAACTCCCGCGTGT 422
 CTGCTTCTCCGGCTGCCACCTGCAGGTCCCAGCTCTTGCTCTCTGCTGTTTGGCTGGAA 482
ATGGCCACGCTTCTCTCTCTTGGGGTGTGGTGGTAAGCCCCAGACGCTCTGGGGAGC 542
 M A T L L L L L L G V L V V S P D A L G S (20)

Exon1'
 Exon1
 Exon2

FIG. 2

EP 0 590 747 A2

1 2 3 4 5 6 7 8




FIG. 3A

1 2 3 4 5



FIG. 3B

EP 0 590 747 A2



FIG. 4B




FIG. 4D




FIG. 4A




FIG. 4C

EP 0 590 747 A2

-219 GTGAAGTCTCAGAAATGGGCGAGGATGTACCTGGAAATCAGCACTAAGTATTGAGCTTCTTAAATGTGCTGCTCTTCAAGATGC
 CGTTGCAGCTCTGATAAATGCAAACTGACAACCTTCAAGGCCACGACGGGAGAAATCATTTGGTCTTGGAGCATAGAGACTGCCCTTCACAAAGGAATCCCTGATTATTGTTGAA
 -1
 ATGCTGAGGAGGCTTGCCTGCGAAGGAGACTTTTCTTATCCCAACCAATACACTTTTATGGTCTCTGTTTATCCCTAATCACCCTTCTCCGTTTAAAGGATTTCATCAAAAGCCTGAATTT
 M L R T L L R R R L F S Y P T K Y Y F M V L V L S L I T F S V L R I H Q K P E F
 120
 40
 GTAAGTGCAGACACTTGGAGCTTGTCTGGGAGAACTCCTAGTAGTGATATTAAATTCACCCAAAGTTTACAGGGTGATGTAAATGAAATCCAAAAGGTAAAGCTTGAGATCCCTAAGAGTG
 V S V R H L E L A G E N P S S O I M C T K V L Q G D V N E I Q K V X L E I L T V
 240
 80
 AAATTTAAAAGGCCCTCGGTGACACCTGACGACTATATAAAGATGACCATGACTGTCTTCTTTCATCAAGAGACGCAATATATTGTAGAACCCCTTAGTAAAGAGAGGCGGAG
 K F K K R P R W T P D D V I N M T S D C S S F I K R R K V I V E P L S K E A E
 360
 120
 TTCCAAATAGCATATTCTATAGTGGTTCATCACAAGATGAAATGCTTGACAGGCTGCTGAGGGCCATCTATATGCCCTCAGAAATTTCTYATTGCTATGTCGACACAAATCCGAGGAT
 F P I A Y S I V V H H K I E M L D R L L R A I Y M P Q N F Y C V H V D T K S E D
 480
 160
 TCCTATTTAGCTGCAGTGATGGGCATCGCTTCTGTTTATAGTAAATGCTTTGTCGCGAGCGGATTGGAGAGTGTGCTTTATGTCATGTCGAGCCGGGTTGAGGCTGACCTCAACTGCATG
 S Y L A A V M G I A S C F S N V F V A S R L E S V V Y A S W S R V Q A D L N C M
 600
 200
 AAGGATCTCTATGCAATGAGTGCAGACTGGAGTACTTGATAAATCTTTGATGGATTTCCTCCCATTAACCAACCACTAGAAATTTGTCAGGAAGCTCAAGTTGTTAATGGGAGAAAC
 K D L Y A W S A N W K Y L I N L C G M D F P I K T M L E I V R K L K L L M G E N
 720
 240

FIG. 5A

EP 0 590 747 A2

AACCTGGAACGGAGGATGCCATCCCATAAAGAGCAAGCTGGAGAGCGGTATGAGGTGCTTAATGSAAGCTGACAAACACAGGGGACTGTCAAAATGCTTCTCCACTCGAAACA
 N L E T E R M P S H K E E R W K K R Y E V V N G K L T N T G T V K M L P P L E T 840
 280
 CCTCTCTTTCTGGCAGTGCCTACTTCGTGGTCAGTAGGGAGTATGTGGGTATGTACTACAGAATCAAAAATCCAAAAGTTGATGGAGTGGGCACCAAGACACATACAGCCCTGATGAG
 P L F S G S A Y F V V S R E Y V G Y V L Q M E K I Q K L M E W A Q D T Y S P D E 960
 320
 TATCTCTGGGCCACCACATCCAAAGGATTCTGAAGTCCCGGGCTCACTCCCTGCCAGCCATAAGTATGATCTATCTGACATGCAAGCAGTTGCCAGGTTTGTCAAGTGGCAGTACTTTGAG
 Y L W A T I Q R J P E V P G S L P A S H K Y D L S D M Q A V A R F V K W Q Y F E 1080
 360
 GGTGATGTTTCAAGGCTCTCCCTACCGCCCTGGCATGGAGTCCATGTGCGTCAAGTGTGCAATTTTGGAGCTGGTCACTTGAAGTGGTCACTTGCAGGTTTGTCAAGTGGCAGTACTTTGAG
 G D V S K G A P Y P C D G V H V R S V C I F G A G D L N W M L R K H L F A N 1200
 400
 AAGTTGACGTGGATGTTGACCTCTTTGCCATCCAGTGTGTTGGATGAGCATTTGAGACACAAAGCTTTGGAGACATTAAGACACTGACCATTTACGGGCAATTTTATGAACAAGAAGAAGG
 X F D V D V D L F A I Q C L D E H L R H K A L E T L K H end 1320
 428
 ATACACAAACGTACCTTATCTGTTTCCCTTCTGTCAGCGTCGGGAAGATGGTATGAAGTCTCTTTGGGCGCAGGGACTCTAGTAGATCTTCTGTCAAGAGCTGATGTTTCT
 GCAGAGCACAGTTAGCTAGAAAGGTATAGCATTAATGTTCTATCTAGAGTTAATAGTGGAGGAGTAAGGTAGCCTTGAGGCCAGAGCAGGTAGCAAGGCATTGTGGAAAGAGGGGAC 1440
 1560
 CAGGGTGGCTGGGGAAGGCCGATGCATAAAGTCAGCCTGTTCCAAGTCTCAGGACTTAGCAAAATGAGAAGATGTGACCTGTGCCAAAACATYTTTGAGAAATTTTAAATGTGACCA
 TTTTTCGGTATGATAAGCTTACAGCAACAAATAATCAAGATACAATTATCTGATATATATTTGTTGAAATAGAAATTTGATTGTACTATAAATGATTTTGTAAATAATTATAT 1680
 1800
 TCTGCTCTAATACTGTACTGTGTAGTGTGCTCCGTATGTCACTCAGGGAGCTTAAATGGGCTTGATTATACATTTGAAGAAAAA
 1886

FIG. 5B



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 590 747 A3**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 93250268.5

(22) Date of filing: 29.09.93

(51) Int. Cl.⁶: C12N 15/54, C12N 9/10,
C12N 15/12, C07K 13/00,
C12N 15/86, C12N 15/64,
C12N 5/10

(20) Priority: 01.10.92 US 955041

(43) Date of publication of application:
06.04.94 Bulletin 94/14

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

(69) Date of deferred publication of the search report:
15.03.95 Bulletin 95/11


(71) Applicant: LA JOLLA CANCER RESEARCH
FOUNDATION
10901 North Torrey Pines Road
La Jolla, CA 92037 (US)

(72) Inventor: Fukuda, Minoru
2818 Passy Avenue
San Diego,
California 92122 (US)
Inventor: Blerhuizen, Mart F. A.
Schiedamsseweg 225
NL-3119 JB Schiedam (US)

(74) Representative: UEXKÜLL & STOLBERG
Patentanwälte
Beselerstrasse 4
D-22607 Hamburg (DE)

(54) A novel-beta1-6 N-acetylglucosaminyltransferase, its acceptor molecule, leukosialin, and a method for cloning proteins having enzymatic activity.

(57) The present invention provides a novel β 1-6 N-acetylglucosaminyltransferase, which forms core 2 oligosaccharide structures in O-glycans, and a novel acceptor molecule, leukosialin, CD43, for core 2 β 1-6 N-acetylglucosaminyltransferase activity. The amino acid sequences and nucleic acid sequences encoding these molecules, as well as active fragments thereof, also are disclosed. A method for isolating nucleic acid sequences encoding proteins having enzymatic activity is disclosed, using CHO cells that support replication of plasmid vectors having a polyoma virus origin of replication. A method to obtain a suitable cell line that expresses an acceptor molecule also is disclosed.



EP 0 590 747 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 93 25 0268

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claims	CLASSIFICATION OF THE APPLICATION (Int. Cl. 5)
D, X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol.86, no.4, February 1989, WASHINGTON US pages 1328 - 1332 ADAM PALLANT ET AL. 'Characterization of cDNAs encoding human leukosialin and localization of the leukosialin gene to chromosome 16' * abstract * * page 1329, left column, paragraph 3 - page 1330, left column, paragraph 4 * * page 1331, right column, paragraph 2 - page 1332, left column, paragraph 1 * ---	9-15	C12N15/54 C12N9/10 C12N15/12 C07K13/00 C12N15/86 C12N15/64 C12N5/10
X	JOURNAL OF BIOLOGICAL CHEMISTRY, vol.266, no.13, 5 May 1991, BALTIMORE, MD US pages 8483 - 8489 SHINICHI KUDO ET AL. 'A short, novel promoter sequence confers the expression of human leukosialin, a major sialoglycoprotein on leukocytes' * abstract * * page 8484, right column, paragraph 2 - page 8485, left column, paragraph 1; figure 2 * --- -/-	9-15	TECHNICAL FIELDS SEARCHED (Int. Cl. 5) C12N C07K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 13 January 1995	Examiner Montero Lopez, B
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date P : document cited in the application L : document cited for other reasons A : number of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 93 25 0268

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CL.5)
X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol.86, no.8, April 1989, WASHINGTON US pages 2819 - 2823 C. SIMON SHELLEY ET AL. 'Molecular characterization of sialophorin (CD43), the lymphocyte surface sialoglycoprotein defective in Wiskott-Aldrich syndrome' * abstract * * page 2820, right column, paragraph 3; figure 2 * * page 2822, left column, paragraph 4 - right column, paragraph 1 * ---	9-15	
X	NUCLEIC ACIDS RESEARCH., vol.19, no.1, 11 January 1991, ARLINGTON, VIRGINIA US pages 85 - 92 MICHAEL HEFFERNAN ET AL. 'Polyoma and hamster papovavirus large T antigen-mediated replication of expression shuttle vectors in Chinese hamster ovary cells' * page 85, right column, paragraph 2 - page 86, left column, paragraph 3 * * page 86, right column, paragraph 3 * * page 87, left column, last paragraph - right column, paragraph 1 * * page 90, left column, paragraph 2 - right column, paragraph 1 * * page 91, left column, last paragraph - right column, paragraph 2 * --- -/--	16-23	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 13 January 1995	Examiner Montero Lopez, B
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure F : intermediate document	

EPO FORM 1503 (01.11.94)